

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 14.68% in the past week and 46.07% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 15.15% and the outperformance increases to 46.48% for the last 4 weeks.

Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 27.3% of Company shares. During last 3 month period, 7.6% of total institutional ownership has changed in the company shares. Shares of RMTI have rallied 37.18% in the last 52 Weeks. On June 24, 2015 The shares registered a 52-week high of \$18.04 and 52-week low was seen on December 15, 2014 at \$8.1. The 50-day moving average is \$11.81 and the 200 day moving average is recorded at \$10.64. S&P 500 has rallied 7.73% during the last 52-weeks. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Friday session in red amid volatile trading. The shares closed down 0.22 points or 1.34% at \$16.17 with 3,076,476 shares getting traded. Post opening the session at \$16.44, the shares hit an intraday low of \$14.94 and an intraday high of \$16.58 and the price vacillated in this range throughout the day. The company has a market cap of \$811 million and the number of outstanding shares has been calculated to be 50,169,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is \$18.04 and the 52-week low is \$8.095. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...